Median Applied sciences Is Releasing Full 12 months 2020 Monetary Outcomes (audited) as Effectively as Q1 2021 Enterprise Exercise Indicators, Displaying a Very Robust Progress

• 2020, a document yr with income of €13.5m, up 51% on 2019

• 2020 outcomes in step with expectations

• Acceleration of the expansion dynamic within the first quarter of 2021 with income of €5.2m, a rise of 86% in comparison with Q1, 2020.

Regulatory Information:

Median Applied sciences (Paris:ALMDT) (Euronext Progress – ALMDT), whose Board of Administrators met on April 6^th, 2021 to approve the consolidated monetary statements for the monetary yr 2020, is immediately releasing its detailed audited full yr monetary outcomes for 2020 in addition to indicators on its enterprise exercise for the primary quarter of 2021.

2020 outcomes in step with expectations, reflecting the investments wanted to speed up development and develop the iBiopsy® platform

The corporate, which revealed indicators on January 14^th, 2021 on its 2020 enterprise exercise, confirms all the weather beforehand communicated. As of December 31^st, 2020:

– Annual income of €13.5m, up 51% on 2019 income (€9m), with fixed quarterly development,
– Money and money equivalents of €16.3m in comparison with €19.4m as of June 30^th, 2020,
– Order backlog¹ of €51.7m, a rise of 35% in comparison with backlog as of December 31^st, 2019 (€38.3m).

In the course of the monetary yr 2020, the typical variety of staff within the Group was 125, with an acceleration of recruitment within the second half of the yr. On December 31^st, 2020, the corporate had 141 staff.

Chosen monetary data (IFRS consolidated monetary statements)

[*] The web monetary consequence ought to be understood as follows:

Given the rise within the firm’s headcount to assist the expansion of the iCRO enterprise (+51% in 2020) and of the iBiopsy® know-how growth, employees prices are up by 37%.

Story continues

The 27% enhance in exterior prices for the yr in comparison with 2019 exterior prices is expounded to:

• the optimisation and deployment of a brand new, extra environment friendly IT infrastructure between Europe, the US and China for the iCRO enterprise and for future cloud-based operations of the iBiopsy® platform,

• elevated prices associated to outsourcing of impartial picture readings for the iCRO enterprise and

• the iBiopsy® associated investments.

Contemplating these parts, the working consequence quantities to -€8.8m.

Within the context of the debt situation linked to the EIB (European Funding Financial institution) mortgage, the Group granted warrants to the EIB. Below IFRS 9, these warrants are derivatives on personal shares and have to be valued at truthful worth via revenue or loss. This debt impacts the web consequence within the consolidated IFRS revenue statements however has and can have no affect on the Group’s money movement.

Acceleration of development in Q1, 2021 and post-closing occasions

As of March 31^st, 2021, the corporate’s quarterly income stands at €5.2m, a rise of 86% in comparison with the income within the first quarter of 2020 (€2.8m). The Group is accelerating its quarterly development momentum with a 27% enhance over This autumn 2020 revenues, marking a tenth consecutive quarter of development.

As of March 31^st, 2021, the order backlog amounted to €52.6m, up from the backlog as of December 31^st, 2020, regardless of a wonderful quarter of invoicing and the cancellation of a venture in China for an quantity of €1.6m.

Money and money equivalents amounted to €39.8m as of March 31^st, 2021. It ought to be famous that the money place was strengthened by the capital enhance by non-public placement concentrating on certified buyers finalised on March 25, 2021 for an quantity of €28.1m, similar to €26.6m web of charges and commissions. The aim of this fundraising is to permit the Firm to finance its actions and fulfil its obligations underneath its contractual commitments with the EIB. The web proceeds of the capital enhance are primarily meant to contribute to the financing of growth operations of the iBiopsy® enterprise, specifically medical validations on the three indications: lung most cancers, main liver most cancers and NASH, in addition to points associated to regulatory and advertising methods. The funds may additionally be used for any venture that might speed up the corporate’s development.

Within the first quarter of 2021, the Group additionally introduced the signing of a serious analysis collaboration with the College of California San Diego. The aim of this collaboration is to conduct a brand new validation examine for the iBiopsy® medical growth plan in Non-Alcoholic Steatohepatitis (NASH), which can be carried out on an impartial cohort of over 300 sufferers. The primary outcomes of this examine are anticipated within the first quarter of 2022.

As well as, the corporate introduced the initiation of a brand new medical growth plan for the early prognosis of lung most cancers, with first outcomes on a cohort of 1,800 sufferers to be revealed within the second half of 2021.

“2020 was a wonderful yr by way of our iCRO enterprise efficiency, inventory efficiency and progress in our iBiopsy® medical growth and partnership plans. The current funding spherical offers us the means to pursue our ambitions to concurrently advance our indications for early prognosis of liver most cancers, NASH and, as lately introduced, lung most cancers as properly,” stated Fredrik Brag, CEO and founding father of Median Applied sciences. “2021 is shaping as much as be a really thrilling yr, with income from our iCRO enterprise already up by 86% within the first quarter in comparison with Q1 income final yr. Our order backlog has elevated regardless of the very important enhance in invoicing. This yr can even see the continued publication of know-how and medical validation outcomes for iBiopsy®, in addition to the continued implementation of our coverage on organising partnerships as a foundation for future growth”.

Median informs its shareholders and the monetary neighborhood that its annual monetary report on the accounts for the yr ended December 31, 2020 was made public and filed with the AMF.

The annual monetary report is on the market on the corporate web site: www.mediantechnologies.com/investors/

Ahead-Trying Statements: This press launch accommodates forward-looking statements. Ahead-looking statements are statements that aren’t historic information. These statements embrace projections and estimates and their underlying assumptions, statements relating to plans, aims, intentions and expectations with respect to future monetary outcomes, occasions, operations, companies, product growth and potential, and statements relating to future efficiency. Ahead-looking statements are usually recognized by the phrases “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and related expressions. Though Median’s administration believes that the expectations mirrored in such forward-looking statements are cheap, buyers are cautioned that forward-looking data and statements are topic to varied dangers and uncertainties, a lot of that are troublesome to foretell and customarily past the management of Median, that would trigger precise outcomes and developments to vary materially from these expressed in, or implied or projected by, the forward-looking data and statements. These dangers and uncertainties embrace amongst different issues, the uncertainties inherent in analysis and growth, future medical knowledge and evaluation, together with submit advertising, choices by regulatory authorities such because the absence of assure that the service if accepted can be commercially profitable, the longer term approval, Median’s capability to learn from exterior development alternatives, to finish associated transactions and/or get hold of regulatory clearances, dangers related to mental property, traits in change charges and prevailing rates of interest, risky financial situations, the affect of price containment initiatives and subsequent modifications thereto, the typical variety of shares excellent in addition to these mentioned or recognized within the public filings with the AMF made by Median, aside from as required by relevant legislation, Median doesn’t undertake any obligation to replace or revise any forward-looking data or statements.

About Median Applied sciences: Median Applied sciences gives revolutionary imaging options and companies to advance healthcare for everybody. We leverage the facility of Imaging Phenomics to offer insights into novel therapies and therapy methods. Our distinctive options for medical picture evaluation and administration in oncology trials and iBiopsy® for imaging phenotyping, along with our world crew of specialists, are advancing the event of latest medicine and diagnostic instruments to observe illness and assess response to remedy. Median Applied sciences helps biopharmaceutical sponsors and healthcare professionals world wide to rapidly and exactly carry new remedies to sufferers in want. That is how we’re serving to to create a more healthy world.

Based in 2002, primarily based in Sophia-Antipolis, France, with a subsidiary within the US and one other one in Shanghai, Median has acquired the label “Revolutionary firm” by BPI France and is listed on Euronext Progress market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME fairness financial savings plan scheme (PEA-PME), is listed on the Enternext® PEA-PME 150 index. The corporate has been awarded the Euronext European Rising Tech label (2020). For extra data: www.mediantechnologies.com

For extra data: www.mediantechnologies.com

¹The order backlog is the sum of orders acquired however not but fulfilled. A rise or lower within the order backlog corresponds to the order consumption of the reporting interval, web of invoiced companies, accomplished or cancelled contracts, and forex affect for initiatives in overseas forex (re-evaluated on the change fee on deadline). Orders are booked as soon as the shopper confirms, in writing, its retention of the Firm’s companies for a given venture. The contract is often signed a couple of months after written affirmation.

View supply model on businesswire.com: https://www.businesswire.com/news/home/20210408005621/en/

Contacts

Median Applied sciences
Emmanuelle Leygues
Head of Company and Advertising and marketing Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Press – ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59
median@alizerp.com

Buyers – ACTIFIN
Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr